Gilead Sciences announced on September 7 that it has enhanced its co-pay and patient assistance programs, including the addition of Stribild, the recently approved single tablet regimen (STR).
Formerly know as "the Quad," Stribild is now part of Gilead's Advancing Access Program, making it available via a Patient Assistance Program (PAP) for people with an annual income of up to 500% Federal Poverty Level (FPL, which is $11,170 per individual), or $55,850 per year for one individual. Stribild will also be listed on the new universal PAP form issued by the Department of Health & Human Services (DHHS).
Gilead has also expanded co-pay assistance for Atripla and Complera and is including Stribild in a program that will now offer up to $400 per month in co-pays, up from $200 previously.
For more information, see the package insert, click here, or call 1-800-GILEAD-5 (1-800-445-3235).
More Like This
Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors
Option to Take Crushed Stribild Tablets With Food or Enteral Nutrition
Stribild (Elvitegravir, Cobicistat, Emtrictiabine, Tenofovir Disoproxil Fumarate) Tablet Label Revised to Expand the Patient Population
Stribild in Women
